Green leaf pharmaceutical Liss' permeable skin patch (multi-day patch) (LY03013) has been approved for clinical trials in China.

Introduction: Liss's permeable skin patch (multi-day patch) is a key product for diseases of the central nervous system.
September 1, Greenlee Pharmaceutical Group Co., Ltd. announced that the Group's permeable skin patch (LY 03013) for the treatment of Alzheimer's disease has been approved by the Drug Review Center of the State Drug Administration of China to start clinical trials.
's permeable patch (multi-day patch) is a key product for central nervous system diseases and developed by the company's German subsidiary, Luye Pharma AG, which is protected globally by multiple patents.
Luye Pharma AG is one of the largest manufacturers of independent permeable systems in Europe, with a highly complex process and a career in technology that has been inspected by GMP in the United States, the European Union and Japan.
Pharma AG's Liss permeable patch (one-day patch) has been approved for listing in more than 20 countries around the world, including some countries in the United States and Europe, and is the first in China to be approved for listing in accordance with the quality and efficacy consistency evaluation requirements.
proportion of single-day stickers, Liss's permeable skin patch (multi-day patch) to improve the patient's drug compliance, reduce the burden of care for caregivers while reducing the socio-economic burden.
Previously, Liss's application for the listing of the permeable patch (multi-day patch) has been officially accepted by Germany, the United Kingdom, Spain, Italy, Glucose Teeth, Luxembourg, Greece, seven European countries, the relevant review workers have been successfully carried out.
addition to Europe and China, the Company intends to register the product in the United States, Japan and other countries.
.